| Brian K Greenberg, MD | |
|
18370 Burbank Blvd, Suite 307, Tarzana, CA 91356-2804 | |
| (818) 996-6000 | |
| (818) 996-4712 |
| Full Name | Brian K Greenberg |
|---|---|
| Gender | Male |
| Speciality | Pediatrics - Pediatric Allergy/immunology |
| Location | 18370 Burbank Blvd, Tarzana, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821023201 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | G61421 (California) | Secondary |
| 2080P0201X | Pediatrics - Pediatric Allergy/immunology | G61421 (California) | Primary |
| Entity Name | Brian K Greenberg Md Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417094418 PECOS PAC ID: 4284056201 Enrollment ID: O20200622000727 |
News Archive
Kaiser Health News staff writer Mary Agnes Carey reports: "By Sept. 23, the six month anniversary of the enactment of the health overhaul, many of the law's provisions will be in effect.
VENITI, Inc., a company dedicated to providing innovative technology for the treatment of venous disease, announced that it has received approval from the United States Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) to begin the VIRTUS trial of the VENITI VICI Venous Stent System.
Many low- and middle-income countries do not have a defined medical specialty in surgical oncology and lack an educational infrastructure to respond to the local burden of cancer, but a Memorial Sloan Kettering Cancer Center fellowship is succeeding in addressing this problem by training foreign medical graduates (FMG) in surgical oncology.
Applying palliative care principles to emergency departments may reduce the number of geriatric patients admitted to intensive care units, possibly extending lives and reducing Medicare costs, according to a three-year analysis by Mount Sinai researchers set to be published in the May edition of Health Affairs, which can be found online.
MedivirAB is an emerging researchbased specialty pharmaceutical company focused on infectious diseases. Medivir today announced that its investigational protease inhibitor TMC435, developed by Tibotec Pharmaceuticals, has successfully completed enrollment of three ongoing global phase 3 trials and further reports that all patients are now on TMC435 or active control treatment.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brian K Greenberg, MD 24422 Avenida De La Carlota Ste 300, Laguna Hills, CA 92653-3628 Ph: (949) 599-2434 | Brian K Greenberg, MD 18370 Burbank Blvd, Suite 307, Tarzana, CA 91356-2804 Ph: (818) 996-6000 |
News Archive
Kaiser Health News staff writer Mary Agnes Carey reports: "By Sept. 23, the six month anniversary of the enactment of the health overhaul, many of the law's provisions will be in effect.
VENITI, Inc., a company dedicated to providing innovative technology for the treatment of venous disease, announced that it has received approval from the United States Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) to begin the VIRTUS trial of the VENITI VICI Venous Stent System.
Many low- and middle-income countries do not have a defined medical specialty in surgical oncology and lack an educational infrastructure to respond to the local burden of cancer, but a Memorial Sloan Kettering Cancer Center fellowship is succeeding in addressing this problem by training foreign medical graduates (FMG) in surgical oncology.
Applying palliative care principles to emergency departments may reduce the number of geriatric patients admitted to intensive care units, possibly extending lives and reducing Medicare costs, according to a three-year analysis by Mount Sinai researchers set to be published in the May edition of Health Affairs, which can be found online.
MedivirAB is an emerging researchbased specialty pharmaceutical company focused on infectious diseases. Medivir today announced that its investigational protease inhibitor TMC435, developed by Tibotec Pharmaceuticals, has successfully completed enrollment of three ongoing global phase 3 trials and further reports that all patients are now on TMC435 or active control treatment.
› Verified 5 days ago
Linda Lea Perl Adatto, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 18370 Burbank Blvd, Suite 307, Tarzana, CA 91356 Phone: 818-996-6000 Fax: 818-996-4712 | |
Dr. Larry Eisenberg, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 18372 Clark St, #216, Tarzana, CA 91356 Phone: 818-705-8559 Fax: 818-705-6475 | |
Jennifer Levy, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 18321 Clark St, Tarzana, CA 91356 Phone: 818-881-0800 | |
Anita Giselle Wright, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 4003 Clarinda Dr, Tarzana, CA 91356 Phone: 818-262-0949 | |
Breahn Faye-merie Donaldson, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 18555 Ventura Blvd Ste B, Tarzana, CA 91356 Phone: 818-614-3088 | |
Malik Oscar White, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 18321 Clark St, Tarzana, CA 91356 Phone: 818-881-0800 | |
Monica P Kandavel, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 18370 Burbank Blvd, Suite 307, Tarzana, CA 91356 Phone: 818-996-6000 Fax: 818-996-4712 |